Celanese (CE) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended September 2025, Celanese (CE) reported revenue of $2.42 billion, down 8.7% over the same period last year. EPS came in at $1.34, compared to $2.44 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $2.46 billion, representing a surprise of -1.69%. The company delivered an EPS surprise of +5.51%, with the consensus EPS estimate being $1.27.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Celanese performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Net Sales- Acetyl Chain: $1.06 billion versus $1.07 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -10.8% change.
- Net Sales- Inter segment eliminations: $-26 million versus $-22.39 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13% change.
- Net Sales- Engineered Materials: $1.38 billion versus $1.38 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -6.6% change.
- Operating EBITDA- Acetyl Chain: $250 million compared to the $258.55 million average estimate based on three analysts.
- Operating EBITDA- Other Activities: $-48 million versus $-49.88 million estimated by three analysts on average.
- Operating EBITDA- Engineered Materials: $315 million versus the three-analyst average estimate of $285.07 million.
View all Key Company Metrics for Celanese here>>>
Shares of Celanese have returned -13.4% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celanese Corporation (CE): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Source Zacks-com
